Effecten van Akkermansia Muciniphila en Berberine Supplementatie op Insulinegevoeligheid bij Ploegendienstwerkers (Shift2Health)
Effecten van Akkermansia Muciniphila- en Berberinesuppletie op Insulinegevoeligheid bij Ploegendienstmedewerkers: een Dubbelblinde, Gerandomiseerde, Placebogecontroleerde, Crossoverstudie binnen het Shift2Health-project
Night shift work is associated with an increased risk of obesity, insulin resistance, and cardiometabolic disorders, largely due to circadian misalignment, disrupted sleep, and altered eating patterns. These behavioral and physiological disturbances impair glucose metabolism and are further influenced by the gut microbiota. In particular, the bacterium Akkermansia muciniphila has been linked to improved metabolic health, including enhanced insulin sensitivity, lipid regulation, and maintenance of intestinal barrier integrity. Berberine, a bioactive plant-derived compound, has demonstrated metabolic benefits, including upregulation of A. muciniphila, improvement of insulin sensitivity, and modulation of lipid metabolism.
Together, these complementary mechanisms suggest that combined A. muciniphila supplementation and berberine administration may synergistically improve metabolic health in shift workers by targeting gut microbiota composition and circadian-regulated metabolic pathways.
Based on this rationale, a double-blind, randomized, placebo-controlled, crossover study is being conducted in 200 night-shift workers from healthcare and industrial sectors in Austria and Denmark. Participants are stratified by age, sex, and work sector and randomly assigned to intervention sequences. Each participant receives either the combined supplement or placebo for 12 weeks, followed by a four-week washout, after which the alternate intervention is administered for another 12 weeks, with a total participation of 28 weeks.
Assessments are performed at four study visits and include anthropometry, body composition, blood pressure, and collection of blood, urine, and feces. Participants complete validated questionnaires on dietary intake, lifestyle, work schedules, and general health to monitor behavioral patterns throughout the study. Dietary intake is recorded for four days prior to each sampling visit in consideration of shift schedules. Sleep duration and quality are monitored via diaries and actigraphy and aligned with dietary records. Circadian variation is minimized by standardizing sampling times and implementing a fasting and synchronization period prior to visits.
The primary outcome is insulin sensitivity, measured by HOMA-IR. Secondary exploratory outcomes include gut microbiota composition and diversity, biomarkers of intestinal permeability and inflammation, lipid profiles, body composition, sleep quality, and dietary behavior.
These measures collectively provide a comprehensive evaluation of the metabolic, microbiome, and circadian effects of combined A. muciniphila and berberine supplementation in night-shift workers.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Miriam Ressler, PhD
- Telefoonnummer: +4331654536677
- E-mail: miriam.ressler@fh-joanneum.at
Studie Locaties
-
-
Styria
-
Graz, Styria, Oostenrijk, 8020
- Werving
- FH JOANNEUM University of Applied Sciences
-
Contact:
- Miriam Ressler, PhD
- Telefoonnummer: +4331654536677
- E-mail: miriam.ressler@fh-joanneum.at
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Health care or industrial shift worker
- Employed or self-employed working ≥ 24 h/week
- Current night shift work (night shift defined as a work schedule that includes at least 3 hours of work between 00:00 and 5:00) with at least 2 consecutive nights/month
- Night shift work duration > 3 years
- 4 or more night shifts/month
Exclusion Criteria:
- BMI of 40 kg/m² or higher
- Pregnancy or planned pregnancy within 6 months of enrolment or breastfeeding women
- Bariatric surgery
- Surgery in the 3 months prior to the study or planned surgery in the next 6 months that, in the opinion of the investigators, could potentially affect the outcome of the study
- Diagnosed diabetes type 1 or type 2
- Uncontrolled thyroid disease (confirmed by clinically significant abnormal TSH/T4 levels without stable medication for more than 3 months)
- Chronic diseases (renal failure, active hepatitis, liver cirrhosis, myocardial infarction within the last 2 years, stroke, chronic obstructive pulmonary disease or cancer)
- Immunodeficiency syndrome, active autoimmune or autoinflammatory disease (e.g. multiple sclerosis, lupus, rheumatoid arthritis), inflammatory bowel disease (e.g. IBS or ulcerative colitis) and acute episodes of atopic diseases (atopic dermatitis, asthma, type 1 allergies such as hay fever). Grave's disease, Hashimoto thyroiditis, Celiac disease, sarcoidosis, Lichen planus, are allowed, if well treated and stable
- Regular intake of anticoagulants
- Known allergy to any inactive or active ingredients in the study products
- Participation in other clinical intervention trials during the study
- Current or planned participation in a weight loss program (including intermittent fasting), extreme diet, or vigorous exercise (e.g., running, fast cycling, swimming laps, or playing intense sports that quickly raise your heart rate)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Verviervoudigen
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: AB Group
Participants will first receive Verum (A) for 3 months. After a 4-week washout period, they will receive Placebo (B) for 3 months. |
1 capsule of A. muciniphila (pasteurized, initial quantity of 3x10^10 TFU, heat inactivated) and 1 capsule of 500 mg berberine hydrochloride per day. 1 capsule of A. muciniphila placebo and 1 capsule of berberine placebo (both identical to verum regarding the shape, size, colour, and matched in excipients) per day. |
|
Experimenteel: BA Group
Participants will first receive Placbo (B) for 3 months. After a 4-week washout period, they will receive Verum (A) for 3 months. |
1 capsule of A. muciniphila (pasteurized, initial quantity of 3x10^10 TFU, heat inactivated) and 1 capsule of 500 mg berberine hydrochloride per day. 1 capsule of A. muciniphila placebo and 1 capsule of berberine placebo (both identical to verum regarding the shape, size, colour, and matched in excipients) per day. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change of 3-months supplementation with A. muciniphila and berberine on insulin resistance using HOMA-IR compared to placebo
Tijdsspanne: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Homeostasis Model Assessment of Insulin Resistance, calculated as (fasting insulin (μU/ml) x fasting glucose (mmol/l)) / 22.5, will be assessed to calculate the change between baseline and endpoint in the two periods |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in gut microbiom composition between the baseline and endpoint change in the two periods
Tijdsspanne: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Gene sequencing of the 16S rRNA is performed on the stool samples to compare microbiota diversity and relative abundance |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in FABPi between the baseline and endpoint change in the two periods
Tijdsspanne: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Measurement of FABP intestinal (FABPi) in blood (pg/mL) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in zonulin between the baseline and endpoint change in the two periods
Tijdsspanne: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Measurement of zonulin in blood (ng/mL) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in LPB between the baseline and endpoint change in the two periods
Tijdsspanne: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Measurement of lipopolysaccharide-binding protein (LPB) in blood (pg/mL) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in CRP between the baseline and endpoint change in the two periods
Tijdsspanne: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Analysis of high-sensitive C-reactive protein (hs-CRP, mg/L) in blood |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in stool short-chain fatty acids (SCFA) between the baseline and endpoint change in the two periods
Tijdsspanne: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
SCFA will be extracted and quantitatively analysed by GC-MS (µmol/g) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in blood lipid profile and cardiovascular markers between the baseline and endpoint change in the two periods
Tijdsspanne: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Measurement of cholesterol (mmol/L), low-density lipoprotein cholesterol (LDL-C, mmol/L), high-density lipoprotein (HDL-C, mmol/L), and triglyceride levels (TG, mmol/L) in blood |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in blood pressure between the baseline and endpoint change in the two periods
Tijdsspanne: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Systolic BP (mmHG) and diastolic BP (mmHG) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in melatonin between the baseline and endpoint change in the two periods
Tijdsspanne: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
6-sulfatoxymelatonin in urine (µg/L) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in BMI between the baseline and endpoint change in the two periods
Tijdsspanne: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Body mass index (BMI) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in body composition between the baseline and endpoint change in the two periods
Tijdsspanne: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Bioelectrical Impedance Analysis (BIA) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in metabolomics at the end of the two periods
Tijdsspanne: At the beginning and the end of each intervention period (week 12, week 28)
|
Metabolomic profiles obtained with LC-MS/MS |
At the beginning and the end of each intervention period (week 12, week 28)
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Medewerkers
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Endocriene systeemziekten
- Ziekten van het zenuwstelsel
- Voedingsstoornissen
- Metabole ziekten
- Overvoeding
- Lichaamsgewicht
- Glucosemetabolismestoornissen
- Suikerziekte
- Hyperinsulinisme
- Hyperglykemie
- Pathologische aandoeningen, tekenen en symptomen
- Voedings- en stofwisselingsziekten
- Tekenen en symptomen
- Overgewicht
- Obesitas
- Insuline-resistentie
- Prediabetische toestand
- Glucose intolerantie
- Chronobiologische stoornissen
Andere studie-ID-nummers
Andere studie-ID-nummers
- 1306/2025
- 101080788 (Ander subsidie-/financieringsnummer: Horizon Europe)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .